Book contents
- Frontmatter
- Contents
- Foreword by Andrew Fire
- Foreword by Marshall Nirenberg
- List of Contributors
- Introduction
- Section one Basic RNAi, siRNA, microRNAs and gene-silencing mechanisms
- Section two Design, synthesis of siRNAs
- Section three Vector development and in vivo, in vitro and in ovo delivery methods
- Section four Gene silencing in model organisms
- Section five Drug target validation
- 22 Delivering siRNA in vivo for functional genomics and novel therapeutics
- 23 The role of RNA interference in drug target validation: Application to Hepatitis C
- 24 RNAi and the drug discovery process
- 25 RNA interference technology in the discovery and validation of druggable targets
- Section six Therapeutic and drug development
- Section seven High-throughput genome-wide RNAi analysis
- Index
- Plate section
- References
25 - RNA interference technology in the discovery and validation of druggable targets
Published online by Cambridge University Press: 31 July 2009
Book contents
- Frontmatter
- Contents
- Foreword by Andrew Fire
- Foreword by Marshall Nirenberg
- List of Contributors
- Introduction
- Section one Basic RNAi, siRNA, microRNAs and gene-silencing mechanisms
- Section two Design, synthesis of siRNAs
- Section three Vector development and in vivo, in vitro and in ovo delivery methods
- Section four Gene silencing in model organisms
- Section five Drug target validation
- 22 Delivering siRNA in vivo for functional genomics and novel therapeutics
- 23 The role of RNA interference in drug target validation: Application to Hepatitis C
- 24 RNAi and the drug discovery process
- 25 RNA interference technology in the discovery and validation of druggable targets
- Section six Therapeutic and drug development
- Section seven High-throughput genome-wide RNAi analysis
- Index
- Plate section
- References
Summary
The role of gene suppression technologies in pharmaceutical drug development
The completion of the human genome sequence (International Human Genome Sequencing Consortium, 2001; Venter et al., 2001) has ushered in a new era for the pharmaceutical industry. With access to a comprehensive list of candidate drug targets, together with a growing understanding of their association to signalling and metabolic pathways and human disease, there would seem to be endless opportunity for novel drug development. From a clinical perspective, this most basic of genetic insights should enhance the efficacy of existing drugs, while at the same time bring new drugs to market for many new therapeutic indications. From a corporate vantage, utilising the information embedded in the human genome for improved target validation should effectively reduce the attrition of candidate drug targets and therefore translate to a “competitive advantage.”
With thousands of candidate drug targets to select from, it is necessary to invest in strategic methods in order to navigate the complex maze of genetic information. Indeed, the identification and validation of targets that map to chemically tractable gene families (the ‘druggable’ genome, or ‘pharmome’) is now recognised as a fundamental challenge to the entire pharmaceutical industry (Figure 25.1). In an effort to achieve this goal, molecular technologies that suppress the expression of a candidate drug target (either in cis- or trans-) have become fixtures in most pharmaceutical R&D programmes, and there are many examples where this has been successful.
- Type
- Chapter
- Information
- RNA Interference TechnologyFrom Basic Science to Drug Development, pp. 347 - 360Publisher: Cambridge University PressPrint publication year: 2005
References
, , , , , , , , , and (2002). Highly efficient gene transfer into primate embryonic stem cells with a simian lentivirus vector. Molecular Therapy, 6, 162–168CrossRefGoogle ScholarPubMed
, , , , , and (2003). Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature, 421, 268–272CrossRefGoogle ScholarPubMed
, and (2000). The metabotropic GABA receptor: molecular insights and their functional consequences. Cellular and Molecular Life Sciences, 57, 635–650CrossRefGoogle ScholarPubMed
and (2000). γ-Aminobutyric acidB receptors: First of the functional metabotropic heterodimers. Journal of Pharmacology and Experimental Therapeutics, 292, 2–7Google Scholar
, and (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550–553CrossRefGoogle ScholarPubMed
, , , and (2003). Germline transmission of RNAi in mice. Nature Structural Biology, 2, 91–92CrossRefGoogle Scholar
, and (2000). GABAB receptors: A new paradigm in G-protein signalling. Molecular and Cellular Neuroscience, 16, 296–312CrossRefGoogle Scholar
, , , , and (2001a). Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494–498CrossRefGoogle Scholar
, and (2001b). RNA interference is mediated by 21– and 22– nucleotide RNAs. Genes & Development, 15, 188–200CrossRefGoogle Scholar
, , and (2002). Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods, 26, 199–213CrossRefGoogle ScholarPubMed
, , , , and (1998). Potent and specific gene interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806–811CrossRefGoogle ScholarPubMed
, , , Ben-, , and (2003). Stable genetic modification of human embryonic stem cells by lentiviral vectors. Molecular Therapy, 7, 281–287CrossRefGoogle ScholarPubMed
, , , and (2001). Identification of essential genes in cultured mammalian cells using small interfering RNAs. Journal of Cell Science, 114, 4557–4565Google ScholarPubMed
, , and (2002). Small interfering RNA and gene silencing in transgenic mice and rats. Federation of European Biochemical Society Letters, 532, 227–230CrossRefGoogle ScholarPubMed
, , , , , , and (2003). An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics, 33, 396–400CrossRefGoogle ScholarPubMed
International Human Genome Sequencing Consortium. (2001). Initial sequencing and analysis of the human genome. Nature, 409, 860–921CrossRef
and (1985). Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science, 229, 345–352CrossRefGoogle ScholarPubMed
, , , and (2000). Signal transduction by GABAB receptor heterodimers. Neuropsychopharmacology, 23 (S4), S42–49CrossRefGoogle Scholar
, , , and (2001). Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in C. elegans. Genome Biology, 2, 1–10Google Scholar
, , , , , , , , , , and (2003). Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature, 421, 231–237CrossRefGoogle ScholarPubMed
, , , , and (2003). Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nature Biotechnology, 21, 559–561CrossRefGoogle ScholarPubMed
, , , and (2002). Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nature Genetics, 32, 107–108CrossRefGoogle ScholarPubMed
, , , and (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science, 295, 868–872CrossRefGoogle ScholarPubMed
, , , , , and (2003). Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science, 299, 2039–2045CrossRefGoogle ScholarPubMed
, , , and (2003). High level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells, 21, 111–117CrossRefGoogle ScholarPubMed
, , and (2002a). siRNA-mediated silencing in T-cells. Journal of Immunology, 169, 5754–5760CrossRefGoogle Scholar
, , , and (2002b). Gene silencing using micro-RNA designed hairpins. RNA, 8, 842–850CrossRefGoogle Scholar
, , , , , , , , and (2002). siRNA-directed inhibition of HIV infection. Nature Medicine, 8, 681–686CrossRefGoogle Scholar
, , , and (2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes & Development, 16, 948–958CrossRefGoogle ScholarPubMed
, , and (2002). Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proceedings of the National Academy of Sciences USA, 99, 2140–2145CrossRefGoogle ScholarPubMed
and , (1998). G protein-coupled receptors: Functional and mechanistic insights through altered gene expression. Physiological Reviews, 78, 35–52CrossRefGoogle ScholarPubMed
, , , , , , , , , and , (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics, 33, 401–406CrossRefGoogle ScholarPubMed
and (2003). Generation of ski-knockdown mice by expressing a long double strand RNA from an RNA polymerase II promoter. Genes & Development, 17, 1340–1345CrossRefGoogle ScholarPubMed
, , , and (2002) Molecular dissection of cytokinesis by RNA interference in Drosophila cultured cells. Molecular Biology of the Cell, 13, 2448–2460CrossRefGoogle ScholarPubMed
, and (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. Journal of Molecular Biology, 327, 761–766CrossRefGoogle ScholarPubMed
, , and (2002). Effect of RNA silencing of polo-like kinase-1 (PLK-1) on apoptosis and spindle formation in human cancer cells. Journal of the National Cancer Institute, 94, 1863–1876CrossRefGoogle Scholar
, and (2003). Transgenic RNAi in mouse oocytes: A simple and fast approach to study gene function. Developmental Biology, 256, 187–193CrossRefGoogle ScholarPubMed
, , and (2000). Selective reduction of dominant maternal mRNAs in mouse oocytes by RNA interference. Development, 127, 4147–4156Google Scholar
, and (2001). Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene, 263, 103–112CrossRefGoogle ScholarPubMed
, and (2003). Ten years of antisense inhibition of brain G-protein coupled receptor function. Brain Research Reviews, 42, 123–142CrossRefGoogle ScholarPubMed
et al. (2001). The sequence of the human genome. Science, 291, 1304–1351CrossRefGoogle ScholarPubMed
and (2000). Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs, 60, 249–271CrossRefGoogle ScholarPubMed
, , , , , , , , and (1998). Heterodimerization is required for the formation of a functional GABAB receptor. Nature, 396, 679–682CrossRefGoogle Scholar
and (2000). Specific interference with gene function by double-stranded RNA in early mouse development. Nature Cell Biology, 2, 70–75CrossRefGoogle ScholarPubMed
and (1994). Measurement of receptor stimulated-guanosine 5′-O-(γ thio) triphosphate binding by G proteins. Methods in Enzymology, 237, 3–13CrossRefGoogle Scholar
, , and (2002). siRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnology, 20, 1006–1010CrossRefGoogle ScholarPubMed
and (2003). Knockouts model the 100 best-selling drugs – will they model the next 100?Nature Reviews Drug Discovery, 2, 38–51CrossRefGoogle ScholarPubMed
and (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences USA, 75, 280–284Google Scholar